Redhill Biopharma Ltd
-0.0049 (-3.50%)


Draw Mode:

Volume 45,470
Bid Price 0.1352
Ask Price 0.14
News -
Company Name Stock Ticker Symbol Market Type
Redhill Biopharma Ltd RDHL NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.0049 -3.5% 0.1352 05:01:03
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume
88 45,470 -
Last Trade Time Type Quantity Stock Price Currency
05:02:04 formt 253  0.1352 USD

Redhill Biopharma Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 12.33M 91.20M 91.20M  85.76M  -82.95M -2.10 -0.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - - -

more financials information »

News Redhill Biopharma

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No RDHL Message Board. Create One! See More Posts on RDHL Message Board See More Message Board Posts

RDHL Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.